The voice of the community pharmacist.

## Getting to the Heart of It Clinical Pearls and Workflow Solutions to Improve Outcomes for Patients on Hypertension Medications

Katherine S. O'Neal, PharmD, MBA, BCACP, CDCES, BC-ADM, AE-C, CLS, FADCES Associate Professor
University of Oklahoma College of Pharmacy

## Disclosure Statement

There are no relevant financial relationships with ACPE defined commercial interests for anyone who was in control of the content of the activity.

## Pharmacist and Technician Learning Objectives

1. Review current hypertension guidelines.
2. List interventions your pharmacy can integrate into workflow to improve care for patients with hypertension.
3. Discuss support staff's role in blood pressure control.

Agenda
-Review of Hypertension

- Blood Pressure Monitoring 101
- Opportunities for Community Pharmacy
-Published Examples
I


號

## Significance

- Individuals at age 50 without hypertension have a 90\% chance of having hypertension by age 80
- Starting at $115 / 75 \mathrm{mmHg}$, cardiovascular risk doubles with every $20 / 10 \mathrm{mmHg}$ increase in blood pressure
- People with treated uncontrolled hypertension or untreated hypertension had higher risk of all-cause, cardiovascular specific, heart disease specific, and cerebrovascular disease specific mortality (treated controlled hypertension did not have the same results)
- In 2020, more than 670,000 deaths had hypertension as the primary or contributory cause


## Prevalence

- 116 million US adults have hypertension ( $47 \%$ )
- 76\% of US adults with hypertension have it uncontrolled
- More men (50\%) than women (44\%) have hypertension
- Highest prevalence is in non-Hispanic black adults (56\%) followed by non-Hispanic white adults (48\%)

Hypertension Prevalence, 2018-2020
Adults, Ages 18+, by County


## CDC Hypertension Cascade



CDC. Figure 1. Hypertension Cascade: Hypertension prevalence, treatment, and control estimates among US adults aged 18

## Categories of Blood Pressure (BP)

| BP Category | Systolic |  | Diastolic |
| :--- | :--- | :--- | :--- |
| Normal | $<120 \mathrm{mmHg}$ | And | $<80 \mathrm{mmHg}$ |
| Elevated | $120-129 \mathrm{mmHg}$ | And | $<80 \mathrm{mmHg}$ |
| Hypertension |  |  |  |
| Stage 1 | $130-139 \mathrm{mmHg}$ | Or | $80-89 \mathrm{mmHg}$ |
| Stage 2 | $\geq 140 \mathrm{mmHg}$ | Or | $\geq 90 \mathrm{mmHg}$ |

## SPRINT Trial

$\left.$|  | Randomized, controlled, open-label trial across 102 clinical sites |
| :--- | :--- |
| Purpose | Identify blood pressure target to reduce cardiovascular morbidity and mortality |
| Participants | 9,361 individuals age $\geq 50$, systolic blood pressure $130-150 \mathrm{mmHg}$ and <br> increased risk of cardiovascular events without diabetes |
| Method | Intensive treatment target $<120 \mathrm{mmHg}$ or standard treatment $<140 \mathrm{mmHg}$ |
| Results | Trial stopped early after 3.26 years | | Significant 25\% reduction in composite outcomes of myocardial infarction, |
| :--- |
| acute coronary syndrome, stroke, acute decompensated heart failure or death |
| from cardiovascular causes (P<0.001) | \right\rvert\, | Significant 27\% reduction in all-cause mortality (P=0.003) |
| :--- |
| Clinical <br> ApplicationFor individuals with high cardiovascular risk, a systolic target of $<120 \mathrm{mmHg}$ <br> results in lower of rates of fatal and nonfatal major cardiovascular events and <br> death from any cause |

## STEP Trial

|  | Randomized, controlled trial across 102 clinical sites |
| :--- | :--- |
| Purpose | Identify blood pressure target to reduce cardiovascular risk in older patients |
| Participants | 8,511 individuals age 60-80 with hypertension <br> Intensive treatment target 110-129 mmHg or standard treatment $130-149$ <br> Method <br> Resug |
| Mean systolic blood pressures were 127.5 mmHg and 135.3 mmHg |  |
|  | Significant 26\% reduction in composite outcomes of stroke, acute coronary <br> syndrome, acute decompensated heart failure, coronary revascularization, <br> atrial fibrillation, or death from CV causes (P=0.007) |
| Clinical <br> Application | For older patients with hypertension, a systolic target of $110-129 \mathrm{mmHg}$ <br> lowered the incidence of CV events |

## Blood Pressure Goal



## Recommended Algorithm



Figure 4 from 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71:e127-e248. Pradhan A, et al. A $20 / 20$ match: ACC/AHA 2017 versus ESC/ESH 2018 guidelines for management of hypertension. Int J Angiol. 2021;30:243-248.

## Nonpharmacological Treatment

| Intervention | Recommendation | Impact on SBP with <br> hypertension | _..SBP with <br> normotension |
| :--- | :--- | :--- | :--- |
| Weight loss | 1 kg reduction in body weight | -5 mmHg | $-2 / 3 \mathrm{mmHg}$ |
| DASH diet | Fruits, vegetables, whole grains, and <br> low-fat dairy | -11 mmHg | -3 mmHg |
| Dietary sodium | $<1500 \mathrm{mg} /$ day | $-5 / 6 \mathrm{mmHg}$ | $-2 / 3 \mathrm{mmHg}$ |
| Dietary potassium | $3500-5000$ mg/day | $-4 / 5 \mathrm{mmHg}$ | -2 mmHg |
| Aerobic physical <br> activity | $90-150$ min/week, $65-75 \%$ heart rate <br> reserve | $-5 / 8 \mathrm{mmHg}$ | $-2 / 4 \mathrm{mmHg}$ |
| Dynamic resistance <br> physical activity | $90-150$ min/week, $50-80 \% 1$ rep <br> maximum, 6 exercises, 3 sets/exercise, <br> 10 repetitions/set | -4 mmHg | -2 mmHg |
| Isometric resistance <br> physical activity | $4 \times 2$ min (hand grip), $30-40 \%$ max <br> voluntary contraction, 3 sessions/week | -5 mmHg | -4 mmHg |
| Moderate alcohol <br> consumption | Men: $\leq 2$ drinks/day <br> Women: $\leq 1$ drink/day | -4 mmHg | -3 mmHg |

SBP: systolic blood pressure

## Pharmacological Treatment

## Thiazide Diuretics

## Calcium <br> Channel Blockers (CCB)

## Angiotensinconverting Enzyme Inhibitors (ACEI)

## Angiotensinreceptor Blockers (ARB)

## Clinical Pearls - Initial Therapy

- Beta blockers are only indicated with initial therapy if there is another comorbid condition such as heart failure or myocardial infarction
- Thiazide-diuretics and CCB are preferred as first line in black patients (except in chronic kidney disease or heart failure, ACEi / ARB preferred)
- Beginning treatment with 2 drugs is recommended when blood pressure is $\geq 20 / 10 \mathrm{mmHg}$ above goal


## Clinical Pearls - Diuretic Updates

- Chlorthalidone vs. hydrochlorothiazide
- No significant difference with reducing risk of myocardial infarction, hospitalized heart failure, or stroke
- Chlorthalidone associated with significantly higher risk of hypokalemia (HR 2.72, CI 2.38-3.12), hyponatremia (HR 1.31, CI 1.16-1.47), acute renal failure (HR 1.37, $\mathrm{Cl} 1.15-1.63$ ), chronic kidney disease (HR 1.24, CI 1.09-1.42) and type 2 diabetes (HR 1.21, CI 1.12-1.30)


## Clinical Pearls - Pregnancy

- Methyldopa
- Calcium channel blockers
- Already established on thiazide or thiazide-like diuretics, okay to continue taking it
- Beta blockers associated with increased rates of cleft lip/palate and cardiovascular and neural tube defects


## CVD Risk Factors

## MODIFIABLE

- Cigarette Smoking
- Diabetes
- Dyslipidemia
- Overweight / Obesity
- Physical Inactivity / low fitness
- Unhealthy Diet


## FIXED

- Chronic kidney disease
- Family history
- Increased age
- Low socioeconomic status / educational status
- Male sex
- Obstructive sleep apnea
- Psychosocial stress


## Performance Measures



## HEDIS Performance



Figure 1. Performance of HEDIS Controlling HBP Measure 1999-2017 (percent of patients with hypertension treated in accordance with the HEDIS Controlling HBP Measure)

## The Impact...

Estimated 3 million ASCVD events could be averted over 10 years with achieving blood pressure target $<130 / 80 \mathrm{mmHg}$
$25 \%$ do not fill initial antihypertensive prescription and after $1^{\text {st }}$ year, medication possession ratio is 50\%

## Blood Pressure Monitoring

## BP Devices



## Digital

Easy to use


Usually stethoscope comes attached

Least expensive

Both manual inflating and automatic inflating available

More
expensive

## Manual Sphygmomanometer

## Team Manual:

- 218 participants, aneroid readings were within 5 mmHg of the mercury monitor $89 \%$ of the time vs. $<44 \%$ of the digital readings
- For the aneroid device, sensitivity $86.7 \%$ and specificity $98.7 \%$ was higher than the digital device


## Team Automated:

- Systematic review of 31 studies including 9,279 participants
- Pooled mean difference of 14.5 mmHg and higher with manual vs. automated



## Validated Device List (VDL)

- Hosted by the American Medical Association and the National Opinion Research Center with input from the FDA, manufacturers, healthcare organizations, and clinicians
www.validatebp.org

| Brands | Device Types |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
| All Brands | All Device Types |  |  |  |
| BrandDevice Type | Name And Model Number | Validation Protocol | Cuffires | Populations Seved |
| A\&D Medical <br> Office | Professional Office Blood Pressure Monitor UM-211 | $\begin{aligned} & \text { I5081060-2:2018/AMD } \\ & \text { 1:2020 } \end{aligned}$ | Extra Large ( $41-50 \mathrm{~cm}$ ), Extra Small 12-17, Large ( $31-45 \mathrm{~cm}$ ), Medium ( $22-32 \mathrm{~cm}$ ), and Smal ( $16-24 \mathrm{~cm}$ ) | General |
| A\&D Medical <br> Office | Professional Office Blood Pressure <br> Monitor <br> UM-212BLE | ISO81060-2:2018/AMD 1:2020 | Extra Large ( $41-50 \mathrm{~cm}$ ), Extra Small 12-17, Large ( $31-45 \mathrm{~cm}$ ), Medium ( $22-32 \mathrm{~cm}$ ), and Smal ( $16-24 \mathrm{~cm}$ ) | General |
| Avita Home | ArmType Blood Pressure Monitor BPM636 | ANSI/AAMI/ISO <br> 81060-2:2013 | Adult (22-42 cm ) | General |

## Selection and Placement of <br> - Use a validated device BP Cuff

- Position the middle of the cuff on the upper arm at the level of the right atrium
- Cuff bladder length should be $\geq 80 \%$ of arm circumference

| Arm <br> Circumference | Usual Cuff Size |
| :--- | :--- |
| $22-26 \mathrm{~cm}$ | Small adult $(12 \times 22 \mathrm{~cm})$ |
| $27-34 \mathrm{~cm}$ | Adult $(16 \times 30 \mathrm{~cm})$ |
| $35-44 \mathrm{~cm}$ | Large adult $(16 \times 36 \mathrm{~cm})$ |
| $45-52 \mathrm{~cm}$ | Adult thigh $(16 \times 42 \mathrm{~cm})$ |

- Cuff bladder width should be $\geq 40 \%$ of arm circumference


## Proper Technique - Patient

1. Avoid smoking, caffeine and exercise 30 minutes before reading
2. Empty bladder
3. Sit in a comfortable chair with back supported for at least 5 minutes and relaxed
4. Both feet flat on the ground and keep legs uncrossed
5. Support or rest arm with cuff on a table at chest height
6. Cuff should be on bare skin
7. Do not talk while blood pressure is being measured

## Proper Technique - Provider

1. Do not talk while measuring blood pressure
2. If first visit, measure both arms and then use arm with higher reading for future readings
3. Inflate cuff $20-30 \mathrm{mmHg}$ above expected
4. Deflate cuff 2 mmHg per second
5. Record systolic as first Korotkoff sound and diastolic as the disappearance of the Korotkoff sound
6. Use an average of $\geq 2$ readings obtained on $\geq 2$ occasions

## BP Changes due to Technique

| Factor | BP Change <br> Systolic/Diastolic $\mathbf{m m H g}$ |
| :--- | :--- |
| Talking | $+10 / 10$ |
| Cuff over clothing | $+5-50 /$ |
| Cuff too small | $+10 / 2-8$ |
| Smoking within 30 minutes | $+6-20 /$ |
| Back unsupported | $+6-10 /$ |
| Arm unsupported, sitting | $+6-8 /$ |

## Broad Impact of Suboptimal Technique



## Service Opportunities Within the Pharmacy

| Hypertension | Weight loss | Diabetes |
| :--- | :--- | :--- |
| Dyslipidemia | Smoking <br> cessation | Cardiovascular <br> risk reduction |

## HEDIS

- Controlling high blood pressure
- Percentage of members age 18-85 who have a diagnosis of hypertension and whose blood pressure is adequately controlled
- Blood pressure control for patients with diabetes
- Percentage of members age 18-85 with diabetes whose blood pressure is adequately controlled


## CMS Star Measures

- Measure = Medication adherence for hypertension RAS antagonists
- Medicare Advantage Part D Score improved from 87.04 in 2022 to 87.20 in 2023
- For Prescription Drug Plans Part D Score improved from 88.45 in 2022 to 88.68 in 2023


## Medication Synchronization

- Program that aligns the refill dates for two or more prescriptions (e.g., Simplify My Meds, StarWellness)
- Meta-analysis of 9 studies found that med sync is associated with greater odds of adherence (OR 2.29, CI 1.99-2.64)


## Target: BP

- Initiative with American Heart Association and American Medical Association
- Program providing support for organizations focusing on improving blood pressure control
- Resources:
- Guidelines
- Free training
- Recognition program


## Flip The Pharmacy

- Key features:
- Appointment based model
- Medication synchronization
- Utilizing non-pharmacy staff (collect information, take blood pressure)
- Follow-up (community health worker, lifestyle coaching)


## Flip The Pharmacy

- Resources:
- Care team coordination
- Guidelines
- eCare plan documentation and SNOMED codes (full case examples on website)
- Workflow


## eCARE Plans and SNOMED Codes

- Link to example documentation form and SNOMED CT descriptions:
- https://www.flipthepharmacy.com/hypertension


## Teamwork! Putting it Altogether

Use pharmacy management system to identify a patient who is several days late filling blood pressure medications

Staff enrolls patients in medication
synchronization

Staff calls patient to schedule a
hypertension review appointment

Pharmacists discusses
blood pressure medication role and lifestyle modifications with patient

Document SNOMED codes for cost effective medication alternatives
and medication
synchronization

Staff obtains \& documents patients blood pressure
eCare plan submitted to patient's primary care physician with recommendations

## Published Examples

## Five Successful Stories...

- Using pharmacy students
- Sole implementation
- Collaborate with academic medical center
- Collaborate with
a health clinic
- Collaborate with a health plan


## Pharmacy Students

| Purpose | Assess the clinical impact of a community IPPE focused on <br> health and wellness by P2 students |
| :--- | :--- |
| Participants | 147 students at 89 community pharmacies (38 independent, <br> 33 chain and 18 grocery) |
| Method | 1-week 40 hour IPPE with three categories of activities: <br> immunizations, health screenings, and patient counseling |
| Results | 985 blood pressure measurements performed |
| Clinical <br> Application | Pharmacy students were able to add value added pharmacy <br> services to the pharmacy, help the surrounding community, <br> and gain needed clinical experiences |

## Academic Medical Center

| Purpose | Explore the perceptions of pharmacists and academic medical center <br> administrators from designing and operationalizing a pharmacist hypertension <br> management program |
| :--- | :--- |
| Participants | 3 community pharmacies and 1 academic medical center <br> MethodPatients with blood pressure $>140 / 90 \mathrm{mmHg}$ were referred to the community <br> pharmacy. Pharmacists obtained blood pressure among other things and <br> made recommendations to the primary care physician. Follow-up occurred <br> every 2-4 weeks until blood pressure was achieved. Pharmacists had access <br> to the EHR. 12 hours of clinical training and 12 hours of EHR training were <br> provided. |
| Results | Community pharmacists were highly satisfied with service and higher job <br> satisfaction |
|  | Physicians responded to clinical notes/inquiries within EHR in 24 hours |

Pharmacists stated workflow was not impacted but they did feel pressure to get back to filling prescriptions

## Family Medicine Clinic

| Purpose | Implement the service, evaluate clinical outcomes, and report financial <br> viability of the partnership |
| :--- | :--- |
| Participants | 1 independent pharmacy (Greenwood Pharmacy) and 1 family medicine clinic <br> (Northeast lowa Family Practice) in Waterloo, lowa |
| Method | 26 patients had at least 1 chronic care management (CCM) encounter which <br> were documented within the EHR. Collaborative practice agreement allowed <br> pharmacists to approve refills as needed and initiate new hypertensive <br> medications. CCM codes 99490, 99487, and 99489 were billed. |
| Results | Medicare reimbursed for the CCM services (99490 \$31, 99487 \$79, 99489 <br> $\$ 43)$ |
| Mean systolic blood pressure decreased from 140.4 to 133.1 mmHg <br> $(P=0.006)$ and diastolic decreased from 77.9 to 75.5 mmHg (P=0.79) |  |
| Total of 6411 minutes logged over the $9-m o n t h ~ s t u d y ~ w i t h ~$ <br> revenue was $\$ 5842$ claims. Total $\$ 2785$ for pharmacy and $\$ 3057$ for clinic) |  |

## Healthcare Plan

| Purpose | Evaluate impact of pharmacists managed hypertensive clinic |
| :--- | :--- |
| Participants | 1 independent community pharmacy (University Pharmacy) and 1 <br> employer wellness plan (Wayne State University employees <br> enrolled in Wellness Warriors Program) in Detroit, MI |
| Method | Participants met with pharmacists or student pharmacists 4 times <br> over a 6-month timeframe, first visit was 45-60 min and <br> subsequent visits were 15-30 min; patients received home blood <br> pressure monitoring kits that had download capability, participants <br> were incentivized by health plan with \$50 after completion of <br> program |
| Results | 152 participants went through program, significant reduction in <br> systolic blood pressure, mean reduction 7.3 mmHg (P<0.001) <br> and diastolic $4.4 \mathrm{mmHg}(\mathrm{P}<0.001)$ |

## Sole Implementation

| Purpose | Describe the implementation and effectiveness of a self-measured blood <br> pressure program in a community pharmacy |
| :--- | :--- |
| Participants | 1 independent pharmacy (L and S Pharmacy) in rural southeast Missouri. <br> Collaboration with the University of Missouri-Kansas City, Mississippi County <br> Health Department, and CPESN-Missouri |
| Method | Pharmacist provided medication therapy management, adherence monitoring, <br> immunizations and reimbursed clinical services. Participants had 4 sessions. <br> SNOMED codes used 3915509 (hypertension education), 50723001 <br> (education), and 135840009 (monitoring) |
| Results | 20 participants with all patients being satisfied with service |
|  | Program took 63 minutes of staff time per patient |
| Systolic blood pressure decreased by 17 mmHg (P=0.001) and diastolic 12 <br> mmHg (P<0.001) |  |
| Labor cost estimated to be $\$ 63.59$ per patient. Reasonable request for <br> \$174/patient |  |

## The Marketing Plan in 3 Key Takeaways

WHY: High prevalence of hypertension (47\%) and uncontrolled hypertension (76\%)

## You can do it!!!

WHO: Train employees and patients to measure blood pressure properly

WHAT, WHERE, and WHEN: Several
3 existing resources (e.g., Flip the Pharmacy) and published methods to help implement services within your pharmacies

## Helpful Resources - Application

- Flip The Pharmacy - Hypertension
- https://www.flipthepharmacy.com/hypertension
- National Committee for Quality Assurance (NCQA)
- https://www.ncqa.org/hedis/measures/
- CMS Star Measures
- https://www.cms.gov/files/document/2023-star-ratings-technicalnotes.pdf


## Helpful Resources - Guidelines

- 2018 ACC/AHA Hypertension Guidelines
- https://www.ahajournals.org/doi/10.1161/HYP. 0000000000000065
- CDC Measure your Blood Pressure
- https://www.cdc.gov/bloodpressure/measure.htm
- Pharmacotherapy Overview
- The Medical Letter: Drugs for Hypertension Vol 62 Issue 1598, 2020


Katherine S. O'Neal, PharmD, MBA, BCACP, CDCES, BC-ADM, AE-C, CLS, FADCES
Associate Professor, University of Oklahoma College of Pharmacy katherine-oneal@ouhsc.edu


